Publication Date:
2010-11-05
Description:
〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Ledford, Heidi -- England -- Nature. 2010 Nov 4;468(7320):18-9. doi: 10.1038/468018a.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21048737" target="_blank"〉PubMed〈/a〉
Keywords:
Antibodies, Monoclonal/adverse effects/economics/therapeutic use
;
Antibodies, Monoclonal, Murine-Derived/adverse effects/biosynthesis/therapeutic
;
use
;
Biological Products/*economics/standards/*supply & distribution/therapeutic use
;
Biotechnology/economics/legislation & jurisprudence
;
Clinical Trials as Topic/trends
;
Drug Approval/legislation & jurisprudence
;
Drug Industry/economics/legislation & jurisprudence
;
Drugs, Generic/adverse effects/*economics/standards/*supply & distribution
;
Europe
;
Humans
;
Marketing/*trends
;
Rituximab
;
United States
;
United States Food and Drug Administration/legislation & jurisprudence
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink